Creative Planning Lowers Stake in Regeneron Pharmaceuticals Inc (REGN)

Creative Planning cut its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 33.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,796 shares of the biopharmaceutical company’s stock after selling 5,451 shares during the quarter. Creative Planning’s holdings in Regeneron Pharmaceuticals were worth $4,059,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Harding Loevner LP increased its stake in shares of Regeneron Pharmaceuticals by 589.2% in the third quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock valued at $286,619,000 after buying an additional 3,131,966 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of Regeneron Pharmaceuticals by 15,495.4% in the second quarter. Janus Henderson Group PLC now owns 1,562,970 shares of the biopharmaceutical company’s stock valued at $767,637,000 after buying an additional 1,552,948 shares in the last quarter. American Century Companies Inc. increased its stake in shares of Regeneron Pharmaceuticals by 2.3% in the third quarter. American Century Companies Inc. now owns 917,554 shares of the biopharmaceutical company’s stock valued at $410,257,000 after buying an additional 20,218 shares in the last quarter. Orbimed Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 22.7% in the third quarter. Orbimed Advisors LLC now owns 572,770 shares of the biopharmaceutical company’s stock valued at $256,097,000 after buying an additional 106,000 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in shares of Regeneron Pharmaceuticals by 0.7% in the third quarter. Legal & General Group Plc now owns 371,110 shares of the biopharmaceutical company’s stock valued at $165,929,000 after buying an additional 2,729 shares in the last quarter. Institutional investors own 66.63% of the company’s stock.

A number of analysts have recently weighed in on the company. BTIG Research restated a “buy” rating and issued a $520.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, November 22nd. BMO Capital Markets set a $444.00 target price on Regeneron Pharmaceuticals and gave the company a “hold” rating in a research note on Monday, November 27th. Citigroup lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the company from $480.00 to $380.00 in a research note on Friday, December 1st. Piper Jaffray Companies restated a “buy” rating and issued a $540.00 target price on shares of Regeneron Pharmaceuticals in a research note on Monday, November 13th. Finally, JPMorgan Chase & Co. restated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, November 28th. Two research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $471.11.

Shares of Regeneron Pharmaceuticals Inc (REGN) opened at $371.53 on Friday. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $39,940.00, a PE ratio of 33.74, a P/E/G ratio of 1.43 and a beta of 1.52. Regeneron Pharmaceuticals Inc has a 12-month low of $340.09 and a 12-month high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.83 by $0.16. The company had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The company’s revenue for the quarter was up 23.0% compared to the same quarter last year. During the same period in the previous year, the company earned $3.13 EPS. analysts anticipate that Regeneron Pharmaceuticals Inc will post 13.55 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Creative Planning Lowers Stake in Regeneron Pharmaceuticals Inc (REGN)” was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this report on another domain, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The correct version of this report can be read at https://stocknewstimes.com/2018/01/21/creative-planning-lowers-stake-in-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply